Invention Grant
- Patent Title: Method of using fusion proteins
- Patent Title (中): 使用融合蛋白的方法
-
Application No.: US13026207Application Date: 2011-02-12
-
Publication No.: US08986698B2Publication Date: 2015-03-24
- Inventor: Barry G. W. Arnason , Mark A. Jensen , David M. White
- Applicant: Barry G. W. Arnason , Mark A. Jensen , David M. White
- Applicant Address: US IL Chicago
- Assignee: Iterative Therapeutics, Inc.
- Current Assignee: Iterative Therapeutics, Inc.
- Current Assignee Address: US IL Chicago
- Agency: Calfee, Halter & Griswold LLP
- Agent Harry J. Guttman
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/38 ; A61K39/395 ; C07K16/28 ; C07K16/00 ; C07K14/765

Abstract:
The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.
Public/Granted literature
- US20110195067A1 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCy RECEPTORS Public/Granted day:2011-08-11
Information query